Table 5.

IFN-γ secretion by T cells in the presence of serum from patients

Cohort 1
T cells/targetNo serum
Patient 2 serum
Patient 3 serum
Patient 4 serum
Patient 6 serum
T cells aloneAnti-idPrePostPrePostPrePostPrePost
MOv-γ T cells vs IGROV-11,26001,10001,0001105507801,2001,460
Melanoma T cells vs Mel 6242,6153,6152,9003,4403,0802,6003,6352,9103,6654,080
Cohort 2
Target cell
Patient 9 T cells as effectors
Patient 10 T cells as effectors
T cells alone
Anti-id
Pt. 9 pre serum
Pt. 9 post serum


T cells alone
Anti-id
Pt. 10 pre serum
Pt. 10 post serum
IGROV-12,5907403,3403901,1701081,8251,550
Allo PBMC3883,3608281,25019935629149
  • NOTE: Cohort 1: MOv-γ-transduced T cells were incubated with FR+ IGROV-1 tumor cells and IFN-γ secretion (pg/mL) determined by ELISA. Inclusion of anti-idiotype antibody in the coculture inhibited redirected T cell activity as expected. Inclusion of posttreatment serum from two patients was also seen to inhibit IFN-γ secretion (bold underlined values). Inhibition of T cells was specific for FR because no decrease in IFN-γ secretion was observed using posttreatment serum with a melanoma-specific T cell line against its cognate target cell. Cohort 2: Posttreatment serum from one patient (Pt. 9) inhibited anti-FR IFN-γ secretion (bold underlined value). Inhibition was specific for FR because no decrease in reactivity to allogeneic stimulator PBMCs was observed.